GSK:BCBA
Glaxosmithkline CEDEAR
၂၀,၉၉၀.၀၀ ARS
arrow_downward
-၀.၇၆%(-၁၆၀.၀၀) 1D
နို ၆, GMT-၃ ၁၇:၅၆:၅၉ · ARS
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
၂၀,၆၂၀.၀၀ ARS
High
၂၁,၃၀၀.၀၀ ARS
Low
၂၀,၆၂၀.၀၀ ARS
Mkt. cap
ဋေ ၁.၀၅ သ
Avg. vol.
၀.၀၀
Volume
၆၃.၀၀
52-wk high
၂၂,၇၆၀.၀၀ ARS
52-wk low
၁၇,၀၁၀.၀၀ ARS
Shares outstanding
၄၀၄.၅၄ ဋေ
No. of employees
၇ သောင်း
Open
၂၀,၆၂၀.၀၀ ARS
High
၂၁,၃၀၀.၀၀ ARS
Low
၂၀,၆၂၀.၀၀ ARS
Mkt. cap
ဋေ ၁.၀၅ သ
Avg. vol.
၀.၀၀
Volume
၆၃.၀၀
52-wk high
၂၂,၇၆၀.၀၀ ARS
52-wk low
၁၇,၀၁၀.၀၀ ARS
Shares outstanding
၄၀၄.၅၄ ဋေ
No. of employees
၇ သောင်း
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၂ နာရီ
Why Is GSK (LSE:GSK) Drawing Attention For New Cancer Data And Proteomics?
Yahoo Finance
·
ပြီးခဲ့သည့် ၂ နာရီ
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
Investing.com
·
ပြီးခဲ့သည့် ၅ နာရီ
GSK at Guggenheim healthcare conference: pushing long-acting biologics
Fortune
·
ပြီးခဲ့သည့် ၈ နာရီ
The CEO job is hard enough to land once. HP’s incoming chief has done it twice
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About Glaxosmithkline CEDEAR
CEOEmma Walmsley | Emma Walmsley
Employees၆.၆၈ သောင်း
Founded၂၀၀၀ ဒီ ၂၇
Headquarters-
SectorHealth Care
Industry-
Websitegsk.com